SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

ABAT is trending due to a massive volume spike and significant price volatility, fueled by community anticipation of a prefeasibility study (PFS) and potential deals. Discussions revolve around the PFS's potential validation of a large NPV, possible government funding, and the company's role in the EV battery supply chain.  Optimism stems from ABAT's lithium extraction and recycling technology, with some comparing it to other successful stocks and anticipating a substantial price increase.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending as community members actively engage in the 'What's UpDog?' joke, driving social media buzz and promoting the Solana-based meme coin. The community highlights its long-standing presence on the Solana blockchain and its listing on Jupiter Strict List, encouraging others to join the UpDog movement. Many users are celebrating that the meme coin has been on the market for a year and a half.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending due to a massive sell-off following mixed Phase 3 trial results, with community members debating whether the nearly 90% drop is an overreaction. Some investors believe the company's cash reserves and other pipeline assets make it a potential rebound play or acquisition target, while others express concern about the drug's efficacy and future prospects. The stock is also gaining attention as traders discuss short squeeze potential and speculate on a possible buyout.

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI is trending amid a recent short report questioning the company's ARR and partnerships, leading to significant volatility and a response from the company rejecting the claims. The community is actively debating the validity of the short report, scrutinizing the company's upcoming earnings for confirmation, and discussing potential legal action against the short seller. Attention is building towards the earnings release scheduled for Wednesday morning, with many anticipating a catalyst that will determine the stock's trajectory.

Ambac Financial Group, Inc. is a holding company, which engages in the provision of financial guarantee insurance policies through its subsidiary, Ambac Assurance Corp. Its services include credit, insurance, asset management and other financial services. The company was founded on April 29, 1991 and is headquartered in New York, NY.

AMBAC Financial Group Inc.

AMBC is trending as investors discuss the potential implications of an upcoming sale in September, with some believing the stock could double based on the value of the sale. Community members highlight the company's cash position and insider buying as positive signals, while also speculating on potential buybacks and acquisitions. The broader discussion involves the company's transformation into a specialty P&C insurance platform and the potential for significant growth.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI.X is trending as community members highlight its significance as the tokenization of Satoshi Nakamoto, the creator of Bitcoin. Many believe it represents the ethos of the entire crypto industry and see it as a must-have for anyone in the space. The community emphasizes the narrative's timelessness and potential for substantial growth, drawing parallels to Bitcoin's early days.

Applied DNA Sciences, Inc. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Applied Dna Sciences Inc

Applied DNA Sciences ($APDN) is trending due to a recent $58M private placement aimed at establishing a BNB-focused digital asset treasury, marking a significant shift towards incorporating cryptocurrency strategies into its biotech business. The community is actively discussing the potential of this move, with some viewing it as a coordinated short trap, while others anticipate a substantial price increase, possibly exceeding $10, due to the company's small float and backing from Binance.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter is trending due to community excitement around the Solana-based $UPDOG token, which is exclusively available for swapping on the Jupiter platform. Community members are actively encouraging others to load up on $UPDOG, highlighting its potential and long-standing presence within the Solana ecosystem. The focus is on the accessibility and community-driven nature of $UPDOG within the broader Solana meme coin landscape.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending due to excitement surrounding its increased ownership stake in the Tanbreeze rare earth mine in Greenland, with expectations of a significant revaluation of the stock. Community discussions focus on the potential impact of this news, along with speculation around government funding and upcoming catalysts. Bullish sentiment is fueled by the strategic importance of rare earth elements and the company's position in the sector.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as investors anticipate upcoming earnings, with some community members expecting volatility and a significant move. Discussions include potential impacts from China, the new SKIMS collaboration, and analyst upgrades, while others express concerns about tariffs and brand perception. Community sentiment is mixed, with debates around potential price movements and the company's long-term prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at...

Forte Biosciences to Host RandD Day December 3, 2024

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will host an R&D Day...

The market’s resilience came under test on Wednesday as apprehensions ahead of earnings from artificial intelligence stalwart Nvidia Corp. (<a class="mention" data-mention="$NVDA" data-symbol-id="NVDA" href="https://stocktwits.com/symbol/NVDA" target="_blank">$NVDA</a>) generated some weakness early in the session.Nvidia stock was last seen trading down more than 1%, giving back some of the nearly 5% gain it made on Wednesday.As traders look ahead to the company’s market-moving&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ai-stalwart-nvidia-to-report-q3-2025-results-wednesday/cJ4UNCxRQC">earnings report,</a> due after the market close, here is a compilation of the most bullish stocks on Stocktwits:Forte Biosciences, In. (<a class="mention" data-mention="$FBRX" data-symbol-id="FBRX" href="https://stocktwits.com/symbol/FBRX" target="_blank">$FBRX</a>)&nbsp;Forte Biosciences shares were last seen rallying over 170% as the nano-cap autoimmune disorders-focused clinical-stage biopharma said its equity financing to support the continuing clinical advancement of its lead candidate FB102 was oversubscribed. “ As a result of the financing, Forte is well capitalized to continue advancing FB102 across autoimmune indications,” it added.Quantum-Si Inc. (<a class="mention" data-mention="$QSI" data-symbol-id="QSI" href="https://stocktwits.com/symbol/QSI" target="_blank">$QSI</a>):Shares of Quantum-Si, a medical-device company that develops a single-molecule detection platform to enable next-gen protein sequencing (NGPS), more than doubled on Wednesday on volumes that are notably above their 3-month average.The upside came after the company made a slew of announcements. Quantum-Si said Avantor, Inc. (<a class="mention" data-mention="$AVTR" data-symbol-id="AVTR" href="https://stocktwits.com/symbol/AVTR" target="_blank">$AVTR</a>) will distribute its NGPS portfolio, providing researchers across the U.S. and Canada access to the portfolio.In a separate release, Quantum-Si announced a collaboration with Nvidia to develop its next proteomics platform called Proteus and advance its core technologies of amino acid binders and amino peptidases using Nvidia AI and accelerated computing.&nbsp;Quantum-Si also announced an expanded partnership with SkyWater Technology, Inc. (<a class="mention" data-mention="$SKYT" data-symbol-id="SKYT" href="https://stocktwits.com/symbol/SKYT" target="_blank">$SKYT</a>) for developing Proetus and a separate deal with its contract manufacturing partner Planet Innovation for the same.&nbsp;Silexion Therapeutics Corp. (<a class="mention" data-mention="$SLXN" data-symbol-id="SLXN" href="https://stocktwits.com/symbol/SLXN" target="_blank">$SLXN</a>)Silexion, a clinical-stage biotech developing RNA interference therapies for certain types of cancers, disclosed in a filing on Tuesday that at the reconvened extraordinary general meeting, its shareholders approved the board recommendation for a reverse split of the shares in the ratio 1-for-9.&nbsp;The penny stock climbed 33% on Wednesday on above-average volume.Duos Technologies Group, Inc. (<a class="mention" data-mention="$DUOT" data-symbol-id="DUOT" href="https://stocktwits.com/symbol/DUOT" target="_blank">$DUOT</a>)Shares of Jacksonville, Florida-based Duos Tech, a software services provider, climbed over 17% after the company announced the signing of a $42 million worth of asset management agreement with Fortress Investment Group to deploy and operate a fleet of mobile gas turbines and balance-of-plant inventory that has a combined generation capacity of 850 megawatts.ZIM Integrated Shipping Services Ltd. (<a class="mention" data-mention="$ZIM" data-symbol-id="ZIM" href="https://stocktwits.com/symbol/ZIM" target="_blank">$ZIM</a>)Cargo shipping firm ZIM Integrated reported <a href="https://stocktwits.com/news-articles/markets/equity/zim-integrated-shipping-stock-rises-premarket-after-strong-q3-earnings/cJ46SQoRXc">upbeat third-quarter earnings</a> and raised its full-year guidance, sending its shares higher by over 7%. Retail hoped for large buyers increasing their exposure to the stock, sending it to the $31-$32 area by the close.<stembedurl>https://stocktwits.com/View2021/message/593365202</stembedurl>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-q3-2025-earnings-imminent/cJ46Z2LRXE">Nvidia Stock Slips Ahead Of Earnings: Gene Munster Explains Why Blackwell Chip Demand Commentary Is Important For Investors</a>

US Stocks dipped ahead of Nvidia earnings but a few sent retailers into a tizzy. 

5 Stocks Retail Investors Are Most Bullish On At Mid-Day

Retailers went overboard about a couple of biotech stocks and a MedTech name, among others on Wednesday.

Equity

Forte Biosciences Inc. (<a class="mention" data-mention="$FBRX" data-symbol-id="FBRX" href="https://stocktwits.com/symbol/FBRX" target="_blank">$FBRX</a>) saw its stock skyrocket by more than 150% on Wednesday afternoon, becoming the top gainer across U.S. markets.&nbsp;Trading volume surged to 19.2 million shares — approximately 1,800 times its daily average — as the stock hit levels last seen over six months ago.&nbsp;FBRX also ranked among the top 10 trending symbols on Stocktwits, with retail sentiment reaching a year’s high.The surge followed Forte’s announcement of an oversubscribed $53 million equity financing, led by high-profile institutional investors including OrbiMed, Janus Henderson Investors, and Tybourne Capital Management.&nbsp;The funds will support clinical development of FB102, Forte’s proprietary anti-CD122 monoclonal antibody targeting autoimmune and autoimmune-related diseases.“This financing by high quality institutional investors is transformative for Forte and highlights the meaningful potential for FB102,” said Forte CEO Paul Wagner.&nbsp;He reiterated that the company’s celiac disease trial is underway, with topline results expected by the second quarter of next year.&nbsp;Forte also plans to expand FB102 into additional indications over the next year, setting up 2025 as a milestone-heavy period for the biopharma company.The company said it will host an R&amp;D Day on Dec. 3 to provide further updates.&nbsp;FBRX remains down nearly 25% year-to-date.&nbsp;<figure class="image"><a href="https://stocktwits.com/symbol/FBRX"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/FBRX_sentiment_and_message_volume_on_Nov_20_fab7daafb7.png" alt="FBRX sentiment and message volume on Nov 20.png" width="1318" height="318"></a><figcaption>FBRX sentiment and message volume on Nov 20 as of 12:00 pm ET | source: Stocktwits</figcaption></figure>Retail investors on Stocktwits were exuberant, driving sentiment to ‘extremely bullish’ (97/100), the highest score since September, and message volume (90/100) to a one-year peak.<stembedurl>https://stocktwits.com/Fanafjell/message/593358026</stembedurl>&nbsp;<stembedurl>https://stocktwits.com/scalp_scalpnyc/message/593340028</stembedurl>Forte last week reported a third-quarter adjusted loss of $4.54 per share, better than analysts’ expectations of a $7.12 loss, despite generating no revenue.&nbsp;The fresh financing positions the company to advance FB102, which it views as a potentially broad-application therapeutic for autoimmune disorders.For updates and corrections, email&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pdyn-rcat-stocks-rise-on-ai-drone-partnership-boost/cJ46NR6RX4">Palladyne, Red Cat Stocks Soar On Expanded AI Drone Collaboration And Key Defense Contract Win: Retail Optimism Grows</a>

Forte also plans to expand FB102 into additional indications over the next year

Forte Biosciences Stock More Than Doubles On Oversubscribed $53M Private Placement: Retail Goes Wild

The funds will support clinical development of FB102, Forte’s proprietary anti-CD122 monoclonal antibody targeting autoimmune and autoimmune-related diseases.

Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced an oversubscribed $53...

Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2024...

Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced second quarter 2024...

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity...

Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced first quarter 2024...

FY2024 EPS Estimates for Forte Biosciences, Inc. Increased by Analyst (NASDAQ:FBRX)

Forte Biosciences, Inc. (NASDAQ:FBRX  Free Report)  Investment analysts at Chardan Capital boosted their FY2024 EPS estimates for shares of Forte Biosciences in a research note issued...

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner in 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

FBRX
Forte Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest FBRX News

FBRX Forte Biosciences Inc